Temocillin susceptibility among Enterobacterales strains recovered from blood culture in France.


Journal

Diagnostic microbiology and infectious disease
ISSN: 1879-0070
Titre abrégé: Diagn Microbiol Infect Dis
Pays: United States
ID NLM: 8305899

Informations de publication

Date de publication:
Jul 2021
Historique:
received: 10 11 2020
accepted: 05 03 2021
pubmed: 5 4 2021
medline: 21 9 2021
entrez: 4 4 2021
Statut: ppublish

Résumé

Temocillin is used for several years in some European countries but, only since 2015 in France. We assessed the susceptibility of Enterobacterales strains isolated from blood culture 1 year before (2014) and 2 years after (2017) its use in France. 1,387 strains were included by 17 clinical laboratories located throughout France: 363 in 2014 and 1,024 in 2017. The rate of resistance to temocillin was 4.6% and 26.7% in 3rd generation cephalosporin (3GC) susceptible and resistant strains respectively. Cephalosporinase-overproducer (COPE) strains were significantly more resistant to temocillin (37.7%) than ESBL-producer (ESBL-PE) (23.5%) (P < 0.01). The rate of temocillin resistance was correlated to the number of inactive beta-lactams. The rate of resistance to temocillin trend to increase from 13.9% in 2014 to 23.9% in 2017 (P < 0.01). Temocillin remains highly active against Enterobacterales but the trend in resistance should be assessed over time.

Identifiants

pubmed: 33813355
pii: S0732-8893(21)00061-4
doi: 10.1016/j.diagmicrobio.2021.115368
pii:
doi:

Substances chimiques

Anti-Bacterial Agents 0
Penicillins 0
temocillin 03QB156W6I

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

115368

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2021 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Competing interest The temocillin Etest strips (bioMérieux, Lyon, France) were provided without charge by Eumedica pharmaceutical.

Auteurs

Eric Farfour (E)

Department of Clinical Biology, Hôpital Foch, Suresnes, France. Electronic address: ericf6598@yahoo.fr.

Anne-Gaëlle Si Larbi (AG)

Department of Clinical Biology, Hôpital Foch, Suresnes, France.

Vincent Cattoir (V)

Department of Microbiology and Hygiene, CHU de Rennes, Rennes, France; National Reference Laboratory for Antibiotic Resistance in Enterococcus Spp, Rennes, France.

Stéphane Corvec (S)

Department of Microbiology and Hygiene, CHU de Nantes, Nantes, France.

Thomas Guillard (T)

Department of Microbiology, CHU de Reims, Reims, France; Inserm UMR-S 1250, Reims, France.

Antoine Grillon (A)

Institut of Bactériology, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.

Christophe Isnard (C)

Normandie Univ, UNICAEN, CHU de Caen Normandie, Department of microbiology, 14000 Caen, France.

Audrey Mérens (A)

Department of Microbiology and Hygiene, Hôpital d'Instruction des Armées Bégin, Saint-Mandé, France.

Nicolas Degand (N)

Department of Microbiology, CHU de Nice, Nice, France.

Typhaine Billard-Pomares (T)

Department of Microbiology and Hygiene, CHU Avicenne, Bobigny, France.

Damien Fournier (D)

Department of Microbiology, CHRU de Besançon, Besançon, France.

Emmanuelle Bille (E)

Department of Microbiology, Hôpital Necker-Enfants Malades, APHP Paris, Paris, France; Institut Necker-Enfants Malades, Université Paris Descartes, INSERM U1151, CNRS UMR 8253, Paris, France.

Cécile Le Brun (C)

Department of microbiology, CHU Bretonneau, Tours, France.

Chloé Plouzeau (C)

Department of Microbiology and Hygiene, CHU de Poitiers, Poitiers, France.

Emilie Flevin (E)

Department of Biology, Hôpital de Dieppe, Dieppe, France.

Nicolas Yin (N)

Department of Microbiology Institut Gustave Roussy, Université Paris-Saclay, Villejuif, France.

Paul-Louis Woerther (PL)

Department of Microbiology, CHU H. Mondor, Créteil, France.

Julie Lourtet (J)

Department of Microbiology, GH Paris - Saint-Joseph, Paris, France.

Philippe Lesprit (P)

Department of Clinical Biology, Hôpital Foch, Suresnes, France.

Alban Le Monnier (A)

Department of Microbiology, GH Paris - Saint-Joseph, Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH